(RTTNews) - Relay Therapeutics, Inc. (RLAY) Monday announced positive interim data for the company's lead drug candidate RLY-2608 in breast cancer patients.
The data showed that despite heavy pre-treatment, patients with PI3Ka-mutated, HR+ (hormone receptor positive), HER2- (human epidermal growth factor receptor 2-) breast cancer who received RLY-2608 in combination with FDA-approved breast cancer treatment, fulvestrant, showed clinically meaningful 9.2-month median progression free survival (PFS). Nearly three quarters of patients experienced tumor reductions.
Further, RLY-2608 plus fulvestrant was generally well tolerated in patients treated across all doses as of the data cut-off date.
RLY-2608 is currently being evaluated in ReDiscover, an ongoing first-in-human study. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone; in combination with fulvestrant; as well as in combination with fulvestrant and ribociclib or atirmociclib.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
